

*Disclaimer :*

*The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.*

**M.10585 - APMH INVEST / UNILABS HOLDING AB**

**SECTION 1.2**

**Description of the concentration**

On 17 December 2021, the Commission received notification of a proposed concentration pursuant to which APMH Invest A/S (“APMHI”) would acquire sole control of Unilabs Holding AB (“Unilabs”). As a result of this transaction, APMHI will acquire sole control over the whole of Unilabs on a lasting basis by way of purchase of shares.

APMHI is established in Denmark and a wholly-owned subsidiary of A.P. Møller Holding A/S (“APMH”). APMH is also the controlling shareholder in A.P. Møller-Mærsk A/S (“APMM”), an integrated transport and logistics company with worldwide activities. APMHI is the company through which APMH conducts its investment activities not related to APMM. For example, APMHI invests in companies that are active globally and holds investments in Maersk Tankers, Maersk Product Tankers, A.P. Moller Capital, KK Wind Solutions Holding A/S, Faerch; Nissens Cooling Solutions, and also holds approximately 41.6% of the shares in Maersk Drilling and approximately 20% of the shares in Danske Bank A/S; is the founder of and (together with certain other institutional investors) an investor in the private equity fund, Africa Infrastructure Fund I; and holds financial investments in fixed income and securities.

Unilabs is a provider of diagnostic services based in Sweden but headquartered in Switzerland. It is active in the provision of bio-medical testing services (also known as CLTS), medical imaging services, reproductive medicine services and drug development services. It has laboratories and/or imaging centres in France, the Netherlands, Slovakia, Sweden, Spain, Czech Republic, Portugal, Denmark, Finland, the UK, Norway, Switzerland, Peru and the United Arab Emirates.